Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | PLOD2 | O00469 | 4/20 | 0.35 |
| ▸ | PLOD3 | O60568 | 3/20 | 0.35 |
| ▸ | PLOD1 | Q02809 | 3/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | PTPRC | P08575 | 2/20 | 0.34 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.34 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5176902 | 0.82 | PLOD2 (0.53) | ALDH1A1KDM4EPLOD2PLOD3PLOD1 | |
| SCHEMBL5563074 | 0.80 | KAT6A (0.45) | GPR119CYP3A4CYP17A1 | |
| SCHEMBL5158637 | 0.80 | PLOD2 (0.59) | HCAR2ALDH1A1PLOD2PLOD3PLOD1 | |
| SCHEMBL30312579 | 0.78 | HCAR2 (0.52) | HCAR2ALDH1A1GPR119TBXA2RTBXAS1 | |
| SCHEMBL27659304 | 0.78 | HCAR2 (0.52) | HCAR2ALDH1A1GPR119TBXA2RTBXAS1 | |
| SCHEMBL29209494 | 0.76 | GAA (0.51) | ALDH1A1 | |
| SCHEMBL5160500 | 0.76 | HCAR2 (0.39) | HCAR2ALDH1A1KDM4EGPR119PLOD2 | |
| SCHEMBL14740837 | 0.76 | CYP17A1 (0.39) | ALDH1A1CYP17A1NAMPT | |
| SCHEMBL768486 | 0.75 | KMT2A (0.57) | ALDH1A1KDM4EPLOD2PLOD3PLOD1 | |
| SCHEMBL14976851 | 0.75 | TAS1R3 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751095-B1 | NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF | SANFORD BURNHAM MED RES INST (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-2751095-B1 | NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF | SANFORD BURNHAM MED RES INST (US) | 2021-10-27 | — | — | EP | disclosed |
| WO-2018226150-A1 | PYRAZOLOPYRIMIDINE AS MALT-1 INHIBITORS | MEDIVIR AKTIEBOLAG (SE) | 2018-12-13 | — | — | WO | disclosed |
| US-9193710-B2 | Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193710-B2 | Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193710-B2 | Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150025064-A1 | NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-01-22 | — | — | US | disclosed |
| US-20150025064-A1 | NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-01-22 | — | — | US | disclosed |
| US-20150025064-A1 | NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-01-22 | — | — | US | disclosed |
| EP-2751095-A2 | NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF | Sanford-Burnham Medical Research Institute (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013033246-A2 | NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF | BRAINCELLS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033246-A2 | NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF | BRAINCELLS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025064-A1 | NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF | GRM1, GRM3, GRM2 | HCAR2 280/4885ALDH1A1 2319/4885KDM4E 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.